Will world-first PBS listing blow BMS’ budget?
By Megan Brodie 3 months ago | In Companies, Products, Reimbursement- 3 months ago
10 August 2026 PBS uptake of BMS’s immunotherapy duo OPDIVO (nivolumab) and YERVOY (ipilimumab) is…
This is subscriber-only content. Please login to continue reading.